PMID- 18043283
OWN - NLM
STAT- MEDLINE
DCOM- 20080114
LR  - 20191210
IS  - 1052-9551 (Print)
IS  - 1052-9551 (Linking)
VI  - 16
IP  - 4
DP  - 2007 Dec
TI  - Fluorescence in situ hybridization (FISH) as primary methodology for the 
      assessment of HER2 Status in adenocarcinoma of the breast: a single institution 
      experience.
PG  - 207-10
AB  - The demand for both reflexed and primary fluorescence in-situ hybridization 
      (FISH) testing in the clinical setting is increasing. Relevant literature has 
      reported the incidence of HER2 overexpression in 20% to 30% of cases, but some 
      reports suggest that HER2 gene amplification rates are substantially lower. 
      Published data, however, on primary FISH assessment from a single institution is 
      limited, especially information about the frequency of the anomalous genotypes 
      defined by FISH. We report our experience with primary FISH testing in 742 
      consecutive cases of breast cancer, in the calendar year 2006. Eighty percent 
      (595/742) of the breast cancer cases were not amplified for HER2 
      (HER2/CEP17=0.8-1.9), whereas 19% (142/742) of cases were HER2 amplified 
      (HER2/CEP17>or=2.0). Among the HER2-amplified cases, 3% (19/742) were low-level 
      amplified (HER2/CEP17 ratio=2.0-2.5). Genotypic heterogeneity, defined as >5% but 
      <50% of the tumor cells demonstrating HER2 gene amplification, was observed in 5% 
      (40/7242) of the cases. HER2 monoallelic deletion (HER2/CEP17<or=0.7) was 
      demonstrated in 2% (12/742) of the cases and CEP17 monosomy (1 CEP17 signal in 
      >80% of tumor cells) was observed in 2% (13/742). Polysomy, if defined as CEP17 
      spot count 3.0 or more in at least 80% of tumor cells, was observed in 3% 
      (20/742) of the cases. These data may be helpful as benchmarks for other 
      institutions initiating primary FISH analysis for HER2 genotyping.
FAU - Tubbs, Raymond R
AU  - Tubbs RR
AD  - Anatomic and Clinical Pathology, Cleveland Clinic Foundation and the Cleveland 
      Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, 
      OH, USA. tubbsr@ccf.org
FAU - Hicks, David G
AU  - Hicks DG
FAU - Cook, James
AU  - Cook J
FAU - Downs-Kelly, Erinn
AU  - Downs-Kelly E
FAU - Pettay, James
AU  - Pettay J
FAU - Hartke, Mary Beth
AU  - Hartke MB
FAU - Hood, Lashonda
AU  - Hood L
FAU - Neelon, Rosemary
AU  - Neelon R
FAU - Myles, Jonathan
AU  - Myles J
FAU - Budd, George Thomas
AU  - Budd GT
FAU - Moore, Halle C
AU  - Moore HC
FAU - Andresen, Steve
AU  - Andresen S
FAU - Crowe, Joseph P
AU  - Crowe JP
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Diagn Mol Pathol
JT  - Diagnostic molecular pathology : the American journal of surgical pathology, part 
      B
JID - 9204924
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/*genetics
MH  - Breast Neoplasms/*genetics
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/*genetics
EDAT- 2007/11/29 09:00
MHDA- 2008/01/15 09:00
CRDT- 2007/11/29 09:00
PHST- 2007/11/29 09:00 [pubmed]
PHST- 2008/01/15 09:00 [medline]
PHST- 2007/11/29 09:00 [entrez]
AID - 00019606-200712000-00003 [pii]
AID - 10.1097/PDM.0b013e318064c72a [doi]
PST - ppublish
SO  - Diagn Mol Pathol. 2007 Dec;16(4):207-10. doi: 10.1097/PDM.0b013e318064c72a.